

HIV | SURVEILLANCE DATA TABLES

**Core Indicators for Monitoring the
Ending the HIV Epidemic Initiative:
(preliminary data):**

**National HIV Surveillance System Data
Reported Through September 2025**



U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE
CONTROL AND PREVENTION

This issue of *HIV Surveillance Data Tables* is published by the Division of HIV Prevention (DHP), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, Georgia.

Data are presented for persons with diagnosed HIV reported to CDC through September 2025.

HIV Surveillance Data Tables is not copyrighted and may be used and copied without permission. Citation of the source is, however, appreciated.

Suggested citation

Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through September 2025. *HIV Surveillance Data Tables* 2025;6(3). <https://www.cdc.gov/hiv-data/initiatives/>. Published February 2026. Accessed [date].

On the Web: <https://www.cdc.gov/hiv-data/initiatives/>

Confidential information, referrals, and educational material on HIV

CDC-INFO

1-800-232-4636 (in English, en Español)

1-888-232-6348 (TTY)

<http://wwwn.cdc.gov/dcs/ContactUs/Form>

Acknowledgments

This issue of *HIV Surveillance Data Tables* was prepared by the HIV Surveillance Branch, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention.

Publication of *HIV Surveillance Data Tables* was made possible by the contributions of the state and territorial health departments and the HIV surveillance programs that provided surveillance data to CDC.

Technical Notes	4
References	6
Tables	
1a HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2024 through September 2025—United States (preliminary)	7
1b HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2024 through September 2025—United States and 6 territories and freely associated states (preliminary)	8
1c HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through September 2025—United States and 6 territories and freely associated states (preliminary)	9
1d HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through September 2025—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	10
2a Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by selected characteristics, January 2024 through June 2025—United States (preliminary)	12
2b Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2024 through June 2025—United States and Puerto Rico (preliminary)	14
2c Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥ 13 years, by area of residence, January 2024 through June 2025—Ending the HIV Epidemic Phase I jurisdictions (preliminary)	16
3 Ending the HIV Epidemic Phase I jurisdictions	19

Technical Notes

The *Ending the HIV Epidemic in the U.S.* (EHE) initiative leverages critical scientific advances in HIV prevention, diagnosis, treatment, and outbreak response [1]. The goal of the initiative is to reduce new HIV infections by 75% by 2025 and by 90% by 2030. The Centers for Disease Control and Prevention (CDC) routinely releases *HIV Surveillance Data Tables* on the core indicators for EHE to allow for more timely monitoring of progress. The full list of EHE core indicators and their definitions can be found in the Technical Notes of the *Core indicators for monitoring the Ending the HIV Epidemic initiative* report, available at <https://stacks.cdc.gov/view/cdc/156512>.

The tables included in this report provide *preliminary* data on HIV diagnoses and linkage to HIV medical care for the years 2024 and 2025 based on cases reported to CDC as of September 2025. Data for the 2 indicators are provided at the national, state, and county levels (EHE Phase I jurisdictions only). See Tabulation and Presentation of Data for details on how the indicators are calculated. More information on HIV surveillance practices and limitations, demographic information, and geographic designations can be found in the Technical Notes for the National HIV Surveillance System (NHSS), available at <https://www.cdc.gov/hiv-data/nhss/>.

TABULATION AND PRESENTATION OF DATA

HIV Diagnoses

HIV diagnoses are the numbers of persons aged ≥ 13 years with HIV diagnosed during January 2024 through September 2025 (Tables 1a–d). Data presented were reported (after the removal of personally identifiable information) to CDC.

An evaluation of surveillance data (2019–2023 diagnoses) found that, on average, approximately 80% of HIV diagnoses are reported to CDC during the year of diagnosis and approximately 98% of HIV diagnoses are reported to CDC by the end of the following year. Data for the years 2024 and 2025 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

More information on counting HIV diagnoses can be found in the *HIV Surveillance Report, 2023*, available at <https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-and-prevalence-2025.html>.

Linkage to HIV Medical Care

Linkage to HIV medical care within 1 month of HIV diagnosis is measured for persons aged ≥ 13 years with HIV diagnosed during January 2024 through June 2025 (Tables 2a–c). The numerator is the number of persons aged ≥ 13 years with HIV diagnosed during January 2024 through June 2025 and who had ≥ 1 CD4 T-lymphocyte (CD4) or viral load (VL) tests within 1 month of HIV diagnosis. The denominator is the number of persons aged ≥ 13 years with HIV diagnosed during January 2024 through June 2025. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to NHSS; therefore, data on linkage to HIV medical care in these surveillance tables are for persons with HIV diagnosed during January 2024 through June 2025 and reported to NHSS through September 2025. Data for the years 2024 and 2025 are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution.

National analyses include data from the United States, including all 50 states and the District of Columbia. While data for Idaho were included in national and regional analyses, they are not presented in jurisdiction-level tables due to the state's lack of mandatory reporting of all CD4 and viral load test results. Conversely, data for Puerto Rico were not included in national and regional analyses but are available in jurisdiction-level tables.

More information on calculating linkage to care can be found in the report *Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 territories and freely associated states, 2023*, available at <https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2025.html>.

References

1. HHS. What is *Ending the HIV Epidemic in the U.S.*?. <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>. Updated September 18, 2025. Accessed December 17, 2025.

Table 1a. HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2024 through September 2025—United States (preliminary)

	No.	No.
	2024	2025 (January–September)
Sex		
Male	30,701	18,735
Female	7,823	4,642
Age at diagnosis (yr)		
13–24	6,819	4,010
25–34	14,078	8,293
35–44	9,072	5,654
45–54	4,701	2,871
55–64	2,834	1,881
≥65	1,020	668
Race/ethnicity^a		
American Indian/Alaska Native	192	138
Asian	817	490
Black/African American	15,212	9,284
Hispanic/Latino	12,873	7,480
Native Hawaiian/other Pacific Islander	89	37
White	8,239	5,425
Multiracial	1,102	523
Transmission category^b		
Male-to-male sexual contact ^c	25,133	15,365
Injection drug use ^d		
Male	1,335	878
Female	1,098	692
Male-to-male sexual contact ^c and injection drug use ^d	1,260	755
Heterosexual contact ^e		
Male	2,942	1,718
Female	6,677	3,912
Other ^f		
Male	31	19
Female	48	39
Region of residence^g		
Northeast	5,658	3,178
Midwest	5,316	3,126
South	19,839	12,619
West	7,711	4,454
Total	38,524	23,377

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through September 2025. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

^a Persons who did not report Hispanic or Latino ethnicity were categorized by race. Hispanic/Latino persons can be of any race.

^b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^c Includes males who have had sexual contact with other males, and males who have had sexual contact with both males and females.

^d Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^e Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^f Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

Table 1b. HIV diagnoses among persons aged ≥ 13 years, by selected characteristics, January 2024 through September 2025—United States and 6 territories and freely associated states (preliminary)

	No. 2024	No. 2025 (January–September)
Sex		
Male	30,993	18,914
Female	7,889	4,681
Age at diagnosis (yr)		
13–24	6,866	4,040
25–34	14,207	8,369
35–44	9,150	5,702
45–54	4,755	2,896
55–64	2,860	1,911
≥65	1,044	677
Race/ethnicity^a		
American Indian/Alaska Native	192	139
Asian	818	490
Black/African American	15,219	9,284
Hispanic/Latino	13,217	7,690
Native Hawaiian/other Pacific Islander	94	37
White	8,240	5,432
Multiracial	1,102	523
Transmission category^b		
Male-to-male sexual contact ^c	25,341	15,506
Injection drug use ^d		
Male	1,347	883
Female	1,100	693
Male-to-male sexual contact ^c and injection drug use ^d	1,270	756
Heterosexual contact ^e		
Male	3,004	1,750
Female	6,740	3,949
Other ^f		
Male	31	19
Female	49	39
Region of residence^g		
Northeast	5,658	3,178
Midwest	5,316	3,126
South	19,839	12,619
West	7,711	4,454
U.S. territories and freely associated states	358	218
Total	38,882	23,595

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are for cases reported to CDC through September 2025. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution. U.S. territories and freely associated states include American Samoa, Guam, the Northern Mariana Islands, Puerto Rico, the U.S. Virgin Islands, and the Republic of Palau.

^a Persons who did not report Hispanic or Latino ethnicity were categorized by race. Hispanic/Latino persons can be of any race.

^b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.

^c Includes males who have had sexual contact with other males, and males who have had sexual contact with both males and females.

^d Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^e Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^f Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

^g Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

Table 1c. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through September 2025—United States and 6 territories and freely associated states (preliminary)

Area of residence	No.	No.
	2024	2025 (January–September)
Alabama	629	423
Alaska	29	18
Arizona	909	484
Arkansas	319	231
California	4,496	2,647
Colorado	486	270
Connecticut	259	117
Delaware	119	90
District of Columbia	186	109
Florida	4,356	2,695
Georgia	2,449	1,543
Hawaii	85	40
Idaho	49	31
Illinois	1,477	660
Indiana	625	385
Iowa	115	95
Kansas	148	85
Kentucky	366	178
Louisiana	845	682
Maine	68	45
Maryland	784	446
Massachusetts	601	296
Michigan	672	497
Minnesota	313	170
Mississippi	482	333
Missouri	579	341
Montana	27	17
Nebraska	137	44
Nevada	609	242
New Hampshire	31	19
New Jersey	1,145	603
New Mexico	147	132
New York	2,495	1,388
North Carolina	1,349	962
North Dakota	21	16
Ohio	918	633
Oklahoma	326	238
Oregon	216	166
Pennsylvania	950	674
Rhode Island	95	31
South Carolina	736	461
South Dakota	35	20
Tennessee	869	613
Texas	5,078	3,001
Utah	188	99
Vermont	14	5
Virginia	856	558
Washington	455	298
West Virginia	90	56
Wisconsin	276	180
Wyoming	15	10
Subtotal	38,524	23,377
U.S. territories and freely associated states		
American Samoa	2	0
Guam	5	0
Northern Mariana Islands	0	0
Puerto Rico	337	218
Republic of Palau	0	0
U.S. Virgin Islands	14	0
Subtotal	358	218
Total	38,882	23,595

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of HIV diagnosis. Numbers less than 12 should be interpreted with caution. Data are for cases reported to CDC through September 2025. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 1d. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through September 2025—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*)

Area of residence	No.	
	2024	2025 (January–September)
Arizona		
Maricopa County	622	336
California		
Alameda County	176	107
Los Angeles County	1,445	871
Orange County	224	178
Riverside County	296	147
Sacramento County	179	68
San Bernardino County	280	149
San Diego County	415	253
San Francisco County	185	128
District of Columbia	186	109
Florida		
Broward County	551	330
Duval County	254	195
Hillsborough County	277	175
Miami-Dade County	1,047	542
Orange County	426	323
Palm Beach County	332	165
Pinellas County	158	89
Georgia		
Cobb County	151	117
DeKalb County	321	211
Fulton County	476	288
Gwinnett County	223	128
Illinois		
Cook County	1,037	417
Indiana		
Marion County	282	150
Louisiana		
East Baton Rouge Parish	118	63
Orleans Parish	133	109
Maryland		
Baltimore City	179	101
Montgomery County	115	59
Prince George's County	234	127
Massachusetts		
Suffolk County	140	68
Michigan		
Wayne County	289	219
Nevada		
Clark County	554	221
New Jersey		
Essex County	282	142
Hudson County	125	63

Table 1d. HIV diagnoses among persons aged ≥ 13 years, by area of residence, January 2024 through September 2025—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)

Area of residence	No.	No.
	2024 (<i>cont</i>)	2025 (January–September) (<i>cont</i>)
New York		
Bronx County	412	244
Kings County	548	280
New York County	332	176
Queens County	416	220
North Carolina		
Mecklenburg County	273	188
Ohio		
Cuyahoga County	146	102
Franklin County	183	158
Hamilton County	121	73
Pennsylvania		
Philadelphia County	380	269
Puerto Rico		
San Juan Municipio	94	64
Tennessee		
Shelby County	314	218
Texas		
Bexar County	382	253
Dallas County	912	491
Harris County	1,278	737
Tarrant County	393	216
Travis County	239	152
Washington		
King County	189	133
Total	18,324	10,622

Abbreviation: CDC, the Centers for Disease Control and Prevention [footnotes only].

Note. Data are based on residence at time of HIV diagnosis. Data are for cases reported to CDC through September 2025. Data are considered preliminary until a 12-month reporting delay has been reached, and should be interpreted with caution.

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2024 through June 2025—United States (preliminary)

	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2024				
Sex					
Male	30,701	25,611	83.4	5,090	16.6
Female	7,823	6,433	82.2	1,390	17.8
Age at diagnosis (yr)					
13–24	6,819	5,598	82.1	1,221	17.9
25–34	14,078	11,789	83.7	2,289	16.3
35–44	9,072	7,549	83.2	1,523	16.8
45–54	4,701	3,867	82.3	834	17.7
55–64	2,834	2,384	84.1	450	15.9
≥65	1,020	857	84.0	163	16.0
Race/ethnicity^a					
American Indian/Alaska Native	192	165	85.9	27	14.1
Asian	817	694	84.9	123	15.1
Black/African American	15,212	12,311	80.9	2,901	19.1
Hispanic/Latino	12,873	11,011	85.5	1,862	14.5
Native Hawaiian/other Pacific Islander	89	72	80.9	17	19.1
White	8,239	6,869	83.4	1,370	16.6
Multiracial	1,102	922	83.7	180	16.3
Transmission category^b					
Male-to-male sexual contact ^c	25,133	21,087	83.9	4,045	16.1
Injection drug use ^d	2,433	1,964	80.7	469	19.3
Male	1,335	1,084	81.2	251	18.8
Female	1,098	880	80.1	218	19.9
Male-to-male sexual contact ^c and injection drug use ^d	1,260	1,019	80.8	241	19.1
Heterosexual contact ^e	9,620	7,910	82.2	1,710	17.8
Male	2,942	2,397	81.5	545	18.5
Female	6,677	5,513	82.6	1,165	17.4
Region of residence^f					
Northeast	5,658	4,904	86.7	754	13.3
Midwest	5,316	4,493	84.5	823	15.5
South	19,839	16,190	81.6	3,649	18.4
West	7,711	6,457	83.7	1,254	16.3
Total^g	38,524	32,044	83.2	6,480	16.8

Table 2a. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by selected characteristics, January 2024 through June 2025—United States (preliminary) (cont)

	Total diagnoses		≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%	
2025 (January–June)						
Sex						
Male	14,222	12,071	84.9	2,151	15.1	
Female	3,530	2,848	80.7	682	19.3	
Age at diagnosis (yr)						
13–24	3,064	2,557	83.5	507	16.5	
25–34	6,355	5,360	84.3	995	15.7	
35–44	4,269	3,590	84.1	679	15.9	
45–54	2,160	1,811	83.8	349	16.2	
55–64	1,408	1,191	84.6	217	15.4	
≥65	496	410	82.7	86	17.3	
Race/ethnicity^a						
American Indian/Alaska Native	106	87	82.1	19	17.9	
Asian	401	350	87.3	51	12.7	
Black/African American	6,980	5,721	82.0	1,259	18.0	
Hispanic/Latino	5,800	5,058	87.2	742	12.8	
Native Hawaiian/other Pacific Islander	32	25	78.1	7	21.9	
White	4,012	3,324	82.9	688	17.1	
Multiracial	421	354	84.1	67	15.9	
Transmission category^b						
Male-to-male sexual contact ^c	11,671	9,958	85.3	1,713	14.7	
Injection drug use ^d	1,183	952	80.5	231	19.5	
Male	651	531	81.6	120	18.4	
Female	532	421	79.1	111	20.9	
Male-to-male sexual contact ^c and injection drug use ^d	584	490	83.9	94	16.1	
Heterosexual contact ^e	4,268	3,482	81.6	786	18.4	
Male	1,301	1,079	82.9	222	17.1	
Female	2,968	2,403	81.0	564	19.0	
Region of residence^f						
Northeast	2,498	2,114	84.6	384	15.4	
Midwest	2,321	2,004	86.3	317	13.7	
South	9,359	7,729	82.6	1,630	17.4	
West	3,574	3,072	86.0	502	14.0	
Total^g	17,752	14,919	84.0	2,833	16.0	

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to CDC; therefore, data on linkage to HIV medical care are for persons with HIV diagnosed during January 2024 through June 2025 and reported to NHSS through September 2025. Data are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution. Small numbers, and percentages based on these numbers, should be interpreted with caution. Data are based on residence at time of HIV diagnosis. National analyses include data from the United States, including all 50 states and the District of Columbia. Data for Idaho were included in national and regional analyses; however, they are not presented in jurisdiction-level tables due to the state's lack of mandatory reporting of all CD4 and viral load test results. Conversely, data for Puerto Rico were not included in national and regional analyses but are available in jurisdiction-level tables.

^a Persons who did not report Hispanic or Latino ethnicity were categorized by race. Hispanic/Latino persons can be of any race.

^b Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person's sex. Because data have been imputed or statistically adjusted to account for missing transmission category, manual calculations of data presented by transmission category may be inaccurate or unreliable and are discouraged. Also, data may not be reported for some populations; therefore, values may not sum to column subtotals and total.

^c Includes males who have had sexual contact with other males, and males who have had sexual contact with both males and females.

^d Includes persons who injected nonprescription drugs or who injected prescription drugs for nonmedical purposes. Also includes injection of drugs prescribed to persons if there is evidence that injection equipment was shared (e.g., syringes, needles, cookers).

^e Heterosexual contact with a person known to have, or with a risk factor for, HIV.

^f Region of residence defined by the U.S. Census Bureau. For more information, see <https://www.census.gov/programs-surveys/economic-census/guidance-geographies/levels.html>. Data are based on residence at time of HIV diagnosis.

^g Includes persons with other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2024 through June 2025—United States and Puerto Rico (preliminary)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2024				
Alabama	629	459	73.0	170	27.0
Alaska	29	24	82.8	5	17.2
Arizona	909	758	83.4	151	16.6
Arkansas	319	257	80.6	62	19.4
California	4,496	3,770	83.9	726	16.1
Colorado	486	371	76.3	115	23.7
Connecticut	259	228	88.0	31	12.0
Delaware	119	99	83.2	20	16.8
District of Columbia	186	154	82.8	32	17.2
Florida	4,356	3,579	82.2	777	17.8
Georgia	2,449	1,987	81.1	462	18.9
Hawaii	85	69	81.2	16	18.8
Illinois	1,477	1,275	86.3	202	13.7
Indiana	625	503	80.5	122	19.5
Iowa	115	102	88.7	13	11.3
Kansas	148	119	80.4	29	19.6
Kentucky	366	292	79.8	74	20.2
Louisiana	845	690	81.7	155	18.3
Maine	68	56	82.4	12	17.6
Maryland	784	687	87.6	97	12.4
Massachusetts	601	533	88.7	68	11.3
Michigan	672	563	83.8	109	16.2
Minnesota	313	277	88.5	36	11.5
Mississippi	482	347	72.0	135	28.0
Missouri	579	465	80.3	114	19.7
Montana	27	27	100	0	0.0
Nebraska	137	110	80.3	27	19.7
Nevada	609	549	90.1	60	9.9
New Hampshire	31	22	71.0	9	29.0
New Jersey	1,145	934	81.6	211	18.4
New Mexico	147	114	77.6	33	22.4
New York	2,495	2,197	88.1	298	11.9
North Carolina	1,349	1,102	81.7	247	18.3
North Dakota	21	18	85.7	3	14.3
Ohio	918	790	86.1	128	13.9
Oklahoma	326	256	78.5	70	21.5
Oregon	216	189	87.5	27	12.5
Pennsylvania	950	833	87.7	117	12.3
Puerto Rico	337	253	75.1	84	24.9
Rhode Island	95	87	91.6	8	8.4
South Carolina	736	649	88.2	87	11.8
South Dakota	35	30	85.7	5	14.3
Tennessee	869	657	75.6	212	24.4
Texas	5,078	4,172	82.2	906	17.8
Utah	188	130	69.1	58	30.9
Vermont	14	14	100	0	0.0
Virginia	856	731	85.4	125	14.6
Washington	455	400	87.9	55	12.1
West Virginia	90	72	80.0	18	20.0
Wisconsin	276	241	87.3	35	12.7
Wyoming	15	13	86.7	2	13.3

Table 2b. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2024 through June 2025—United States and Puerto Rico (preliminary) (cont)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
	2025 (January–June)				
Alabama	342	220	64.3	122	35.7
Alaska	12	8	66.7	4	33.3
Arizona	433	383	88.5	50	11.5
Arkansas	157	131	83.4	26	16.6
California	2,108	1,812	86.0	296	14.0
Colorado	200	154	77.0	46	23.0
Connecticut	99	82	82.8	17	17.2
Delaware	64	51	79.7	13	20.3
District of Columbia	80	66	82.5	14	17.5
Florida	1,868	1,583	84.7	285	15.3
Georgia	1,165	970	83.3	195	16.7
Hawaii	26	20	76.9	6	23.1
Illinois	533	471	88.4	62	11.6
Indiana	290	228	78.6	62	21.4
Iowa	69	65	94.2	4	5.8
Kansas	68	54	79.4	14	20.6
Kentucky	138	118	85.5	20	14.5
Louisiana	477	400	83.9	77	16.1
Maine	40	34	85.0	6	15.0
Maryland	333	297	89.2	36	10.8
Massachusetts	245	230	93.9	15	6.1
Michigan	343	299	87.2	44	12.8
Minnesota	127	111	87.4	16	12.6
Mississippi	237	185	78.1	52	21.9
Missouri	231	195	84.4	36	15.6
Montana	13	13	100	0	0.0
Nebraska	38	34	89.5	4	10.5
Nevada	238	207	87.0	31	13.0
New Hampshire	13	12	92.3	1	7.7
New Jersey	494	389	78.7	105	21.3
New Mexico	99	92	92.9	7	7.1
New York	1,051	900	85.6	151	14.4
North Carolina	680	572	84.1	108	15.9
North Dakota	13	13	100	0	0.0
Ohio	450	391	86.9	59	13.1
Oklahoma	179	141	78.8	38	21.2
Oregon	117	108	92.3	9	7.7
Pennsylvania	534	447	83.7	87	16.3
Puerto Rico	187	144	77.0	43	23.0
Rhode Island	19	17	89.5	2	10.5
South Carolina	355	273	76.9	82	23.1
South Dakota	15	13	86.7	2	13.3
Tennessee	433	344	79.4	89	20.6
Texas	2,397	2,004	83.6	393	16.4
Utah	75	58	77.3	17	22.7
Vermont	3	3	100	0	0.0
Virginia	411	336	81.8	75	18.2
Washington	218	190	87.2	28	12.8
West Virginia	43	38	88.4	5	11.6
Wisconsin	144	130	90.3	14	9.7
Wyoming	5	3	60.0	2	40.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to CDC; therefore, data on linkage to HIV medical care are for persons with HIV diagnosed during January 2024 through June 2025 and reported to NHSS through September 2025. Data are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution. Small numbers, and percentages based on these numbers, should be interpreted with caution. Data are based on residence at time of HIV diagnosis. Data for Idaho were included in national and regional analyses; however, they are not presented in jurisdiction-level tables due to the state's lack of mandatory reporting of all CD4 and viral load test results. Conversely, data for Puerto Rico were not included in national and regional analyses but are available in jurisdiction-level tables.

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2024 through June 2025—Ending the HIV Epidemic Phase I jurisdictions (preliminary)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
		2024			
Arizona					
Maricopa County	622	527	84.7	95	15.3
California					
Alameda County	176	163	92.6	13	7.4
Los Angeles County	1,445	1,200	83.0	245	17.0
Orange County	224	202	90.2	22	9.8
Riverside County	296	228	77.0	68	23.0
Sacramento County	179	144	80.4	35	19.6
San Bernardino County	280	208	74.3	72	25.7
San Diego County	415	360	86.7	55	13.3
San Francisco County	185	174	94.1	11	5.9
District of Columbia	186	154	82.8	32	17.2
Florida					
Broward County	551	448	81.3	103	18.7
Duval County	254	200	78.7	54	21.3
Hillsborough County	277	226	81.6	51	18.4
Miami-Dade County	1,047	835	79.8	212	20.2
Orange County	426	360	84.5	66	15.5
Palm Beach County	332	283	85.2	49	14.8
Pinellas County	158	123	77.8	35	22.2
Georgia					
Cobb County	151	129	85.4	22	14.6
DeKalb County	321	273	85.0	48	15.0
Fulton County	476	382	80.3	94	19.7
Gwinnett County	223	193	86.5	30	13.5
Illinois					
Cook County	1,037	905	87.3	132	12.7
Indiana					
Marion County	282	233	82.6	49	17.4
Louisiana					
East Baton Rouge Parish	118	97	82.2	21	17.8
Orleans Parish	133	109	82.0	24	18.0
Maryland					
Baltimore City	179	159	88.8	20	11.2
Montgomery County	115	99	86.1	16	13.9
Prince George's County	234	205	87.6	29	12.4
Massachusetts					
Suffolk County	140	130	92.9	10	7.1
Michigan					
Wayne County	289	239	82.7	50	17.3
Nevada					
Clark County	554	499	90.1	55	9.9
New Jersey					
Essex County	282	218	77.3	64	22.7
Hudson County	125	102	81.6	23	18.4
New York					
Bronx County	412	357	86.7	55	13.3
Kings County	548	457	83.4	91	16.6
New York County	332	297	89.5	35	10.5
Queens County	416	370	88.9	46	11.1
North Carolina					
Mecklenburg County	273	236	86.4	37	13.6

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2024 through June 2025—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (cont)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
2024 (cont)					
Ohio					
Cuyahoga County	146	129	88.4	17	11.6
Franklin County	183	164	89.6	19	10.4
Hamilton County	121	100	82.6	21	17.4
Pennsylvania					
Philadelphia County	380	325	85.5	55	14.5
Puerto Rico					
San Juan Municipio	94	68	72.3	26	27.7
Tennessee					
Shelby County	314	215	68.5	99	31.5
Texas					
Bexar County	382	307	80.4	75	19.6
Dallas County	912	755	82.8	157	17.2
Harris County	1,278	1,039	81.3	239	18.7
Tarrant County	393	332	84.5	61	15.5
Travis County	239	217	90.8	22	9.2
Washington					
King County	189	167	88.4	22	11.6
Total	18,324	15,342	83.7	2,982	16.3
2025 (January–June)					
Arizona					
Maricopa County	299	263	88.0	36	12.0
California					
Alameda County	87	78	89.7	9	10.3
Los Angeles County	700	596	85.1	104	14.9
Orange County	122	111	91.0	11	9.0
Riverside County	107	92	86.0	15	14.0
Sacramento County	63	53	84.1	10	15.9
San Bernardino County	132	97	73.5	35	26.5
San Diego County	215	190	88.4	25	11.6
San Francisco County	99	95	96.0	4	4.0
District of Columbia	80	66	82.5	14	17.5
Florida					
Broward County	235	198	84.3	37	15.7
Duval County	123	93	75.6	30	24.4
Hillsborough County	110	92	83.6	18	16.4
Miami-Dade County	394	337	85.5	57	14.5
Orange County	231	198	85.7	33	14.3
Palm Beach County	125	107	85.6	18	14.4
Pinellas County	64	48	75.0	16	25.0
Georgia					
Cobb County	94	80	85.1	14	14.9
DeKalb County	156	134	85.9	22	14.1
Fulton County	214	183	85.5	31	14.5
Gwinnett County	96	83	86.5	13	13.5
Illinois					
Cook County	350	317	90.6	33	9.4
Indiana					
Marion County	117	99	84.6	18	15.4

Table 2c. Linkage to HIV medical care within 1 month of HIV diagnosis among persons aged ≥13 years, by area of residence, January 2024 through June 2025—Ending the HIV Epidemic Phase I jurisdictions (*preliminary*) (*cont*)

Area of residence	Total diagnoses	≥1 CD4 or VL tests		No CD4 or VL test	
	No.	No.	%	No.	%
2025 (January–June) (<i>cont</i>)					
Louisiana					
East Baton Rouge Parish	47	35	74.5	12	25.5
Orleans Parish	76	66	86.8	10	13.2
Maryland					
Baltimore City	78	73	93.6	5	6.4
Montgomery County	46	37	80.4	9	19.6
Prince George’s County	85	81	95.3	4	4.7
Massachusetts					
Suffolk County	54	50	92.6	4	7.4
Michigan					
Wayne County	153	128	83.7	25	16.3
Nevada					
Clark County	217	190	87.6	27	12.4
New Jersey					
Essex County	119	94	79.0	25	21.0
Hudson County	50	39	78.0	11	22.0
New York					
Bronx County	191	156	81.7	35	18.3
Kings County	218	189	86.7	29	13.3
New York County	125	105	84.0	20	16.0
Queens County	169	144	85.2	25	14.8
North Carolina					
Mecklenburg County	136	128	94.1	8	5.9
Ohio					
Cuyahoga County	80	75	93.8	5	6.3
Franklin County	110	102	92.7	8	7.3
Hamilton County	56	45	80.4	11	19.6
Pennsylvania					
Philadelphia County	209	185	88.5	24	11.5
Puerto Rico					
San Juan Municipio	59	45	76.3	14	23.7
Tennessee					
Shelby County	155	120	77.4	35	22.6
Texas					
Bexar County	197	166	84.3	31	15.7
Dallas County	397	330	83.1	67	16.9
Harris County	581	479	82.4	102	17.6
Tarrant County	177	152	85.9	25	14.1
Travis County	113	97	85.8	16	14.2
Washington					
King County	92	81	88.0	11	12.0
Total	8,203	7,002	85.4	1,201	14.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/mm³ or cells/μL) or percentage; VL, viral load (copies/mL); CDC, the Centers for Disease Control and Prevention [footnotes only]; NHSS, National HIV Surveillance System [footnotes only].

Note. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. Reporting of linkage to HIV medical care data requires a minimum 3-month reporting delay to account for delays in reporting of laboratory results to CDC; therefore, data on linkage to HIV medical care are for persons with HIV diagnosed during January 2024 through June 2025 and reported to NHSS through September 2025. Data are considered preliminary until a 12-month reporting delay has been reached and should be interpreted with caution. Small numbers, and percentages based on these numbers, should be interpreted with caution. Data are based on residence at time of HIV diagnosis.

Table 3. Ending the HIV Epidemic Phase I jurisdictions

Counties	Territories	States
Arizona	Puerto Rico	Alabama
Maricopa County	San Juan Municipio	Arkansas
California		Kentucky
Alameda County		Mississippi
Los Angeles County		Missouri
Orange County		Oklahoma
Riverside County		South Carolina
Sacramento County		
San Bernardino County		
San Diego County		
San Francisco County		
District of Columbia		
Florida		
Broward County		
Duval County		
Hillsborough County		
Miami-Dade County		
Orange County		
Palm Beach County		
Pinellas County		
Georgia		
Cobb County		
DeKalb County		
Fulton County		
Gwinnett County		
Illinois		
Cook County		
Indiana		
Marion County		
Louisiana		
East Baton Rouge Parish		
Orleans Parish		
Maryland		
Baltimore City		
Montgomery County		
Prince George's County		
Massachusetts		
Suffolk County		
Michigan		
Wayne County		
Nevada		
Clark County		
New Jersey		
Essex County		
Hudson County		
New York		
Bronx County		
Kings County		
New York County		
Queens County		

Table 3. Ending the HIV Epidemic Phase I jurisdictions (cont)

Counties	Territories	States
North Carolina		
Mecklenburg County		
Ohio		
Cuyahoga County		
Franklin County		
Hamilton County		
Pennsylvania^a		
Philadelphia County		
Tennessee		
Shelby County		
Texas		
Bexar County		
Dallas County		
Harris County		
Tarrant County		
Travis County		
Washington		
King County		

Note. For more information on the Ending the HIV Epidemic in the U.S. initiative, see <https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview>.